Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, imipenem / cilastatin / relebactam (Recarbrio®) cannot be endorsed for use within NHS Wales for the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options. |
||
|
||
Medicine details |
||
| Medicine name | imipenem / cilastatin / relebactam (Recarbrio®) | |
| Formulation | 500 mg / 500 mg / 250 mg powder for solution for infusion | |
| Reference number | 3792 | |
| Indication | Treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options |
|
| Company | Merck Sharp & Dohme Ltd | |
| BNF chapter | Infections | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 04/08/2020 | |